BEDMINSTER, N.J.--(BUSINESS WIRE)--Somnus Therapeutics, Inc., a private specialty pharmaceutical company, has been granted approximately $245,000 under the Qualifying Therapeutic Discovery Project (QTDP) to help fund clinical trials of SKP-1041, a delayed-release tablet formulation of zaleplon. Phase 1 clinical data presented in June 2010, at the SLEEP 2010 Meeting suggests that SKP-1041 allows natural sleep induction in subjects and prevents middle of the night awakening without next-day cognitive or motor effects, thus addressing an important unmet need among insomnia sufferers.
